Genor Biopharma Holdings Limited (FRA:67N0)

Genor Biopharma Holdings Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,010	1,059	1,165	1,589	2,201	2,930
Cash & Short-Term Investments	1,010	1,059	1,165	1,589	2,201	2,930
Cash Growth	-1.62%	-9.15%	-26.64%	-27.81%	-24.89%	1055.63%
Other Receivables	27.2	8.5	68.63	82.7	132.53	136.44
Receivables	27.2	8.5	68.63	82.7	132.53	136.44
Inventory	-	-	5.67	47.4	49.65	31.47
Other Current Assets	-	-	1.34	1.34	3.76	3.76
Total Current Assets	1,037	1,067	1,241	1,720	2,387	3,101
Property, Plant & Equipment	4.53	5.82	60.14	205.22	223.37	229.16
Long-Term Investments	83.84	83.73	-	-	-	-
Goodwill	-	17.82	17.82	21.75	21.75	21.75
Other Intangible Assets	168.66	82.65	92.28	141.46	149.29	135.18
Long-Term Deferred Tax Assets	9.14	8.92	8.35	6.91	5.73	5.64
Other Long-Term Assets	21.51	23.5	27.17	19.6	76.12	80.3
Total Assets	1,325	1,290	1,447	2,115	2,863	3,573
Accounts Payable	172.13	90.59	152.21	156.77	153.48	108.75
Accrued Expenses	7.86	11.5	21.86	40.86	58.66	42.24
Short-Term Debt	-	-	-	-	29.7	-
Current Portion of Leases	0.36	0.36	3.23	6.76	7.6	15.05
Current Income Taxes Payable	-	1	1.84	2.24	3.51	2.35
Current Unearned Revenue	4.03	5.85	8.59	8.59	9.34	8.59
Other Current Liabilities	26.18	12.8	41.79	45.18	50.9	71.75
Total Current Liabilities	210.55	122.09	229.53	260.4	313.19	248.73
Long-Term Leases	0.39	0.56	3.92	21.82	20.11	16.01
Long-Term Unearned Revenue	4.34	4.26	10.57	13.98	18.15	22.66
Long-Term Deferred Tax Liabilities	10.33	10.8	11.6	12.44	13.28	14.13
Other Long-Term Liabilities	0.48	0.35	0.56	1.23	5	34.8
Total Liabilities	226.09	138.05	256.18	309.87	369.73	336.32
Common Stock	0.07	0.07	0.07	0.07	0.07	0.07
Additional Paid-In Capital	9,489	9,478	9,398	9,376	9,291	9,188
Retained Earnings	-6,896	-6,842	-6,790	-6,116	-5,386	-4,521
Treasury Stock	-0.75	-0.75	-5.2	-5.2	-5.2	-6.81
Comprehensive Income & Other	-1,494	-1,484	-1,414	-1,452	-1,410	-1,426
Total Common Equity	1,099	1,151	1,189	1,802	2,490	3,234
Minority Interest	0.07	0.2	1.89	2.74	2.92	3.07
Shareholders' Equity	1,099	1,152	1,191	1,805	2,493	3,237
Total Liabilities & Equity	1,325	1,290	1,447	2,115	2,863	3,573
Total Debt	0.75	0.91	7.16	28.59	57.41	31.06
Net Cash (Debt)	1,009	1,058	1,158	1,560	2,143	2,899
Net Cash Growth	-1.39%	-8.67%	-25.75%	-27.21%	-26.06%	1268.87%
Net Cash Per Share	1.94	2.06	2.29	3.09	4.32	11.84
Filing Date Shares Outstanding	521.21	516.81	504.07	501.93	495.84	489.03
Total Common Shares Outstanding	521.21	516.81	503.73	501.45	495.84	489.03
Working Capital	826.56	945.21	1,012	1,460	2,073	2,853
Book Value Per Share	2.11	2.23	2.36	3.59	5.02	6.61
Tangible Book Value	929.98	1,051	1,079	1,639	2,319	3,077
Tangible Book Value Per Share	1.78	2.03	2.14	3.27	4.68	6.29
Machinery	-	180.48	202.09	287.56	288.38	266.42
Construction In Progress	-	6.43	6.43	9.68	13.73	3.81
Leasehold Improvements	-	89.32	85.18	84.4	84.4	82.46

Source: S&P Global Market Intelligence. Standard template. Financial Sources.